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Background: Pneumonia in people with dementia has been associated with severe discomfort. We sought to
assess the effectiveness of a practice guideline for optimal symptom relief for nursing home residents with
dementia and pneumonia.
Methods: A single-blind, multicenter, cluster randomized controlled trial was conducted in 32 Dutch nursing homes.
Outcomes were assessed on the patient level. The main outcome measures were discomfort and symptoms: discomfort
(DS-DAT: Discomfort Scale-Dementia of Alzheimer Type), (lack of) comfort (EOLD-CAD: End Of Life in Dementia-Comfort
Assessment in Dying), pain (PAINAD: Pain Assessment in Advanced Dementia), and respiratory distress (RDOS: Respiratory
Distress Observation Scale). Outcomes were scheduled daily from diagnosis until 10 days later and a final time between
13–15 days from diagnosis by trained observers who were blinded to the intervention and the residents’ condition and
treatment. In a pre-intervention phase, usual care was provided to all homes. In the intervention phase, matched clusters
of homes were randomized to either the control (n= 16) or intervention condition (n = 16).
Results: Between 1 January 2012 and 1 May 2015, 464 episodes of pneumonia were included. Outcomes were obtained
for 399 episodes in 367 residents. Longitudinal multilevel linear regression analyses were performed on log-transformed
outcomes, so coefficients should be interpreted as a ratio, and a coefficient of 1 means no difference. The practice
guideline in the intervention phase did not reduce the level of discomfort and symptoms: DS-DAT: 1.11 (95 % CI 0.93–1.
31), EOLD-CAD: 1.01 (95 % CI 0.98–1.05), PAINAD: 1.04 (95 % CI 0.93–1.15), RDOS: 1.11 (95 % CI 0.90–1.24). However, in
both the intervention and control groups, lack of comfort and respiratory distress gradually decreased during the entire 3.
5 years of data collection, and were lower in the intervention phase compared to the pre-intervention phase: DS-DAT: 0.93
(95 % CI 0.85–1.01), EOLD-CAD: 0.98 (95 % CI 0.97–1.00), PAINAD: 0.96 (95 % CI 0.91–1.01), RDOS: 0.92 (95 % CI 0.87–0.98).
Conclusions: When compared to usual care, the practice guideline for optimal symptom relief did not relieve discomfort
and symptoms in nursing home residents with dementia and pneumonia. However, discomfort and symptoms decreased
gradually throughout the data collection in both the intervention homes and the control homes. An intervention that
focuses on creating awareness may be more effective than a physician practice guideline.
Trial registration: The Netherlands National Trial Register (ID number NTR5071. Registered 10 March 2015).
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Nursing home residents with dementia and pneumonia
experience severe discomfort which increases in the six
days preceding death [1, 2]. Discomfort occurs regard-
less of treatment with antibiotics or not. Residents dying
from pneumonia experienced more discomfort than resi-
dents dying of other causes [3]. Moreover, death from
respiratory infections has been associated with the lar-
gest symptom burden before death. For example, 78 %
experienced respiratory distress compared to 40 % and
23 % for residents dying from a cardiovascular disorder
or dehydration/cachexia, respectively [4]. Nowadays,
comfort is increasingly accepted to be a primary goal of
treatment for residents with dementia, especially — but
not exclusively — for those nearing death. However, evi-
dence on the best way to maximize comfort for these
residents is scarce.
Because residents with dementia are often unable to
express their complaints and wishes about treatment, re-
lieving the symptoms of pneumonia in these residents is
particularly challenging, and palliative care guidelines
directed towards the treatment of symptoms in other
populations lack applicability. In contrast to chronic
progressive diseases such as cancer, for which guidelines
are developed, pneumonia is an acute intercurrent dis-
ease with specific symptoms. Until recently, no specific
guidelines were available, and no studies have tested
evidence-based recommendations to intervene in usual
care to relieve discomfort in residents with dementia
and pneumonia.
We developed a practice guideline for optimal relief of
the symptoms of pneumonia specifically for residents with
dementia, based on existing guidelines, the available litera-
ture, and consensus among a multidisciplinary and inter-
national expert panel in a Delphi study [5]. This practice
guideline provides targeted treatment recommendations
and a checklist including observational instruments for
the monitoring of pneumonia symptoms. We hypothe-
sized that the practice guideline would enhance comfort
by regular observations to monitor symptoms, by provid-
ing a more structured treatment approach and also by in-
creasing awareness of discomfort. We assessed the effects
of the introduction of this evidence- and consensus-based
practice guideline on the level of observed discomfort,
(lack of) comfort, pain, and respiratory distress (in brief:
discomfort and symptoms) from the diagnosis of pneumo-
nia until cure or death within 15 days. We compared the
practice guideline with usual care (randomized part of the
study) but also over time (comparison over time).
Methods
Design, setting, and inclusion
We conducted a single-blind, multicenter cluster random-
ized controlled trial in 32 nursing homes (the clusters)covering 11 of 12 provinces from January 2012 until May
2015. The cluster randomized design was chosen so that
physicians would not have patients randomized to use of
the guideline and non-use of the guideline, as physicians
could always use the guideline once familiar with it. The
trial period comprised a pre-intervention phase (be-
fore randomization) and an intervention phase (after
randomization) to allow for adjusting for changes in the
outcomes over time. Dutch nursing homes employ elderly
care physicians, who are responsible for all medical care
and treatment decisions after having followed a 3-year spe-
cialist training in elderly care medicine that includes, for
example, training in advance care planning and decision
making in end-of-life care [6–8]. Based on a clinical diag-
nosis (pneumonia as most probable diagnosis), attending
physicians included all episodes of pneumonia (multiple
episodes per resident possible) in residents with dementia
who resided on wards that participated in the study.
Outcome measures
The study’s primary outcome measures were discomfort
and important symptoms for persons with pneumonia:
pain and respiratory distress. Improving comfort was the
primary goal of the intervention, and it may be the pri-
mary care goal for patients with advanced dementia.
Pain and respiratory distress were also assessed, as these
are burdensome symptoms and are commonly ex-
perienced by patients with dementia in the dying phase
[4, 8, 9]. We assessed residents’ discomfort using the val-
idated Discomfort Scale-Dementia of Alzheimer Type
(DS-DAT) [10, 11]. Additionally, we measured (lack of )
comfort with the End Of Life in Dementia-Comfort
Assessment in Dying (EOLD-CAD) [12, 13]; pain, using
the Pain Assessment in Advanced Dementia (PAINAD)
[14, 15]; and respiratory distress with the Respiratory
Distress Observation Scale (RDOS) [16, 17]. These
observational instruments are described in more detail
elsewhere [1].
The level of sleepiness was also observed, because be-
ing unconscious or asleep may positively affect comfort
[1]. A six-level scale (“awake and alert,” “awake,” “awake
but sleepy,” “falling asleep,” “in a light sleep,” and “in a
deep sleep”) was used as a continuous scale in analyses.
Additionally, we registered the use of visible non-
pharmacological measures such as extra pillows to im-
prove posture or oxygen administration.
Data collection
Observers who did not know the residents or the unit
they visited performed the observations, to ensure they
remained blind to the residents’ condition, treatments,
and the intervention. Observers had various back-
grounds [1]; some were nursing home staff working on
wards not participating in the study, and others, such as
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home. The research team trained all 229 observers
(mean 7, range 1–14 per home) in using the observa-
tional instruments using the same program that included
an instructional video and training with videotaped resi-
dents to increase the reliability of observations.
Observations of all outcomes preferably started at the
day of diagnosis (further referred to as day 0), and from
then on observations were planned twice a day at day 0
and day 1, once a day from day 2 until day 10, and one
last time at day 13, 14, or 15 (Fig. 1). We limited the
total observation period to 15 days because cure from
pneumonia or death were both expected by this time
[2]. Observations were scheduled at roughly the same
times each day, and not during meals or shortly after po-
tentially burdensome procedures such as transfers,
washing, or toileting. Each observation took approxi-
mately 10 minutes.
We allowed fewer than the maximum number of 13 ob-
servations, prioritizing regular observations, i.e., avoiding
consecutive missed observations. Reasons for missing ob-
servations were a limited availability of trained observers,
e.g., during the weekends, and late inclusion by the attend-
ing physician (i.e., after the day of diagnosis). We had
regular scheduled e-mail contact with the observers in all
homes during the study period to discuss any problems in
data collection and ways to resolve them.
Other measures and treatments
At the time a pneumonia episode was included (Fig. 1),
the attending physician provided demographics, speci-
fied whether the resident had a treatment goal primarily
directed at comfort (comfort goal) or otherwise (cure or
life prolongation), and provided a clinical judgment of
illness severity (scale ranging from 1 (not ill) to 9 (mori-
bund)) [18]. Questionnaire 1 (Q1), completed within0 2 4 6 8 101 3 5 7 9
Diagnosis pneumonia and inclusion 
Q1
Days from diagnosis 
Fig. 1 Timeline of data collection. Q1 questionnaire 1, Q2 questionnaire 2,
assess outcomes on day 0 and day 1 (2 times a day), daily for days 2–10 an
at the time of diagnosis of pneumonia, completed Q1 within 2 days from
when a resident died during the data collection within 14 days from (regis
consider observational data, inclusion of Q1 and Q2, and survival2 days from the diagnosis of pneumonia, addressed
symptoms of pneumonia at time of the diagnosis and
treatments initiated to relieve symptoms. In question-
naire 2 (Q2), completed between 1 and 3 weeks from
diagnosis, physicians provided the following: treatments
initiated to relieve symptoms at follow-up, the severity
of dementia using the 7-item Bedford Alzheimer Nurs-
ing Severity Scale (BANS-S) [19], whether there was full
dependency on seven activities of daily living (ADL)
items (dressing, transfer, eating, toilet use, personal hy-
giene, bed mobility, locomotion on unit) [20], and de-
gree of dependency in three distinct activities (dressing,
walking, and eating), each assessed on a 5-point scale.
Physicians also provided data about urinary incontin-
ence, comorbid diseases, nutritional and hydration sta-
tus, and delirium as judged by the physician. To
estimate the risk of dying within 2 weeks when treated
with antibiotics, we used a validated 8-item prognostic
score (range 0–31) [21].
Randomization
Nursing homes (clusters) started with the pre-intervention
phase of the study, in which care as usual was provided.
During this pre-intervention phase, homes were asked to
include residents with pneumonia, who were observed
following the observation protocol, while physicians pro-
vided data about the residents’ condition and treatments as
described previously. After a minimum of 6 months, a
maximum of 24 months, and after reporting at least four
residents with pneumonia, participating nursing homes
were randomized. One year before the end of the data col-
lection (May 2014), the last 11 homes were randomized
even if homes had included only one or two residents in
the pre-intervention phase.
Within groups of homes, two smaller groups that
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Q3 questionnaire 3, X day of death. Observers were scheduled to
d once on day 13, 14, or 15. Attending physicians included residents
diagnosis, Q2 between 7 days and 21 days from diagnosis, and Q3
tration of) death. Data analyzed for the purpose of this article only
Table 1 Contents of the practice guideline
The intervention
A consensus- and literature-based practice guideline for optimal
symptom relief for residents with pneumonia and dementia
Practice guideline components:
1. Checklist of symptoms
2. Observational instruments to monitor symptoms*
3. Tailored treatment recommendations
4. Poster displaying key points and action plan
*Respiratory
distress
RDOS: Respiratory Distress Observation Scale
*Pain PAINAD: Pain Assessment in Advanced Dementia
PACSLAC: Pain Assessment Checklist for Seniors with
Limited Ability to Communicate
REPOS: Rotterdam Elderly Pain Observation Scale
Action plan:
A. Suspected pneumonia in resident with pneumonia and dementia
B. Right away: complete checklist
C. Optional: use the RDOS to asses respiratory distress
D. Optional: observe pain using one of three instruments
E. Consult relevant treatment recommendations
F. Re-use the checklist on days 1, 2, and 3 and 7 days after pneumonia
diagnosis
G. Repeat steps at a later time and monitor symptoms using the
checklist and observational instruments
Key points:
- Treatment advice is grouped into supportive care and
(non)pharmacological treatments
- The practice guideline is suitable for all treatment goals, including
cure or palliation
- The practice guideline is intended as a decision aid; the physician is
of course free to deviate from it if there are good clinical reasons
- Administering a low dose of opioids can provide relief of the overall
condition of the resident, regardless of the treatment goal
The practice guideline was expected to enhance comfort by:
- Enhancing awareness with regard to discomfort
- Providing a more structured treatment approach
- Ensuring regular observations to monitor symptoms
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dementia), (2) the location in the urbanized central west
region of the country or elsewhere, and (3) the level of dis-
comfort measured in the pre-intervention phase (average
DS-DAT score on observation day 2) were randomized to
either the control group or intervention group by drawing
lots in opaque, sealed envelopes. After the randomization
procedure was finished, the total number of beds was
similar in the control group (16 homes) and the interven-
tion group (16 homes) (control 1652 (mean 103), inter-
vention 1700 (mean 106)). Likewise, the number of homes
located in the urbanized west region of the country (con-
trol 10, intervention 9) and pre-intervention discomfort
(mean DS-DAT score: control 8.2, intervention 8.2) were
not different.
The intervention
The contents and key points of the practice guideline
are listed in Table 1; more details on its contents and de-
velopment are described elsewhere [5]. Practice guide-
line components were (1) a checklist with symptoms of
pneumonia, (2) observational instruments to monitor
the symptoms of pain and respiratory distress, and (3)
tailored treatment recommendations about supportive
care, non-pharmacological treatment, and pharmaco-
logical treatment for nine symptoms related to pneumo-
nia (Table 1). Physicians were instructed to use the
different components of the practice guideline at their
own discretion. Using the guideline was not mandatory,
so we were unable to assess physician’s adherence to
specific guideline recommendations. Our recommenda-
tions for use were to: (1) thoroughly read the practice
guideline at least once before treating or including pa-
tients, (2) for a specific patient, use the checklist to
monitor symptoms and assess symptoms at diagnosis,
use it daily on the two days after diagnosis, and one last
time seven days after diagnosis, (3) use observational in-
struments in the case of suspected respiratory distress or
pain, and (4) use the tailored treatment recommenda-
tions in the guideline in response to the completed
checklist or the patient’s condition.
The intervention was introduced in all intervention
homes during a 1-hour meeting at the start of the inter-
vention phase, and physicians were supposed to apply it
with individual patients. During the study period, physi-
cians were reminded to use the practice guideline by
monthly reminder e-mails, a semi-annual newsletter,
and regular phone calls. Physicians were instructed to
use the practice guideline and its components at their
own discretion. In the control homes, residents with de-
mentia and pneumonia received usual care to relieve
symptoms. At the transition to the intervention phase in
control homes, an evaluation meeting was organized, in
which we addressed the assignment to the controlgroup, the study’s progress in general, and the process in
the particular nursing home. Control homes were told
that an intervention for optimal symptom relief was in-
troduced in the intervention homes, but they were not
informed about its contents, format, or possible mecha-
nisms to enhance comfort.
Sample size
We based the sample size calculations on the number of
pneumonia episodes rather than on the repeated obser-
vations within a pneumonia episode. The time point on
which we could observe the largest difference in
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tion group was not determined in advance, because the
exact day on which the maximum effect is expected de-
pends on several factors, such as severity of illness, the
moment (symptom-relieving) treatment was started
(directly after pneumonia diagnosis or later), and what
treatment was initiated. When symptom-relieving treat-
ments such as analgesics are provided, effects on observed
discomfort are expected soon after administration. With
antibiotics, relief of symptoms, if any, would be expected
from about 48 hours after administration. Further, we
chose the outcome measure discomfort (DS-DAT) as a
basis, and used an estimated incidence of pneumonia of
0.095 episode per psychogeriatric bed per year [22]. We
assumed nursing homes would participate with an average
of 125 beds on psychogeriatric wards (mostly dementia)
and that observations were started on time for five of six
episodes of pneumonia. Based on these assumptions, a
maximum intracluster correlation of 0.20, a significance
level (α) of 0.05 (two-tailed), and a power (1 – -β) of 0.80,
at least 12 homes per group were needed for the DS-DAT,
5 homes for the PAINAD, and 20 homes for the EOLD-
CAD to detect a clinically relevant difference at some days
of the observation period between the intervention homes
and the control homes of 3 points on the DS-DAT
(assuming a standard deviation (SD) of 2.98) [23] and the
EOLD-CAD (assuming an SD of 3.43) [12] and 1.5 points
on the PAINAD (assuming an SD of 1) [15]. The mean
values were robust estimates, as they were based on 3, 4,
and 2 observations, respectively.
Analyses
We calculated the incidence of pneumonia by summing
incident cases of pneumonia during the months that
homes participated in the study. We included data on
“missed episodes”: pneumonia episodes that met the in-
clusion criteria but were not included in the study, as re-
ported retrospectively by the physicians. Descriptive
statistics were used for resident characteristics, symp-
toms of pneumonia, and treatments to relieve symptoms.
To compare residents between and within groups, inde-
pendent t tests, chi-square tests, and a Mann–Whitney U
test (length of stay) were used.
We used longitudinal multilevel linear regression
analyses and added the binary variable intervention phase
(0 = pre-intervention phase, 1 = intervention phase) to the
model, as well as an interaction term for intervention
phase and group (control or intervention). We modeled
the outcome variables as a function of group (control or
intervention) and intervention phase (pre-intervention
phase or intervention phase) to account for pre-
intervention differences between the groups. The inter-
vention effect is reflected by the difference between
intervention homes and control homes in the interventionphase, adjusted for the pre-intervention phase. We used
an additional longitudinal multilevel linear regression
model to assess differences between the pre-intervention
and the intervention phase irrespective of the intervention
on the four primary outcomes.
Outcome variables were log transformed because data
were not normally distributed, except for observation
days 0 and 1. Therefore, coefficients should be inter-
preted as a ratio, so that a coefficient of 1 means no dif-
ference. For all analyses, a random intercept on the
“pneumonia episode level” was added to adjust for de-
pendency of the repeated measures for each episode of
pneumonia. To account for clustering of the pneumonia
episodes within the participating homes, a random inter-
cept was added at the nursing home level.
To assess possible differential intervention effects, we
added interaction terms for group and intervention
phase with (1) residents’ observed level of sleepiness and
(2) death within 20 days or not. We did so because dis-
comfort and symptoms may be different for residents
observed awake or asleep and for residents who died
within 20 days, because descriptive analyses of pre-
intervention data showed an increase in discomfort in
the six days preceding death [1] and because the EOLD-
CAD has been developed for residents who are dying.
When interactions were significant, we followed with
subgroup analyses. We intended to perform subgroup
analyses for residents treated with or without antibiotics,
but these analyses were omitted as the proportion of res-
idents who were not treated with antibiotics was too
small [1]. With a sensitivity analysis, we examined effects
when observations performed on the day of diagnosis
were omitted, because the efficacy of some treatments,
e.g., treatment with antibiotics, is expected only after the
first day. Moreover, we examined whether results dif-
fered if only the first pneumonia episode per resident
was included (exclusion of 24 non-first episodes). In ex-
ploratory analyses, we adjusted for observed sleepiness
to examine if this altered the effect of the intervention,
as decreasing consciousness could be a purpose of the
intervention, e.g., with palliative sedation.
We adjusted all analyses for the a priori determined co-
variates sex, age, dementia severity (BANS-S score), type
of dementia (Alzheimer’s or other), death within 20 days,
and season (spring, summer, autumn, winter; because eti-
ology and population may be different), and for baseline
differences. The latter included resident characteristics
and symptoms at baseline that differed within or between
groups (type of dementia “mixed,” “other,” or “unknown,”
full dependency in ADLs, dependency in dressing and eat-
ing, the number of comorbid diseases, hydration status, el-
evated body temperature, coughing, tachypnea, decreased
alertness, and sputum production). We checked whether
adjusting for a priori determined covariates alone altered
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ing data (a maximum of 7 % of the residents and 5 % of
the observations), we applied multiple imputation with 20
imputations, after which data were pooled according to
Rubin’s rules for analyses with data of all residents [24]. In
analyses on subgroups of the data, adjusted analyses were
performed on single imputed data for covariates (imput-
ation of the variable mean for continuous variables, and of
mode for dichotomous variables) rather than on multiple
imputed data, after we had confirmed that differences in
coefficients and confidence intervals between analyses
performed on multiple or single imputation were only
minor.
The statistical significance level was set to 0.05 for all
analyses. Multilevel linear regressions and multiple impu-
tations (Multivariate Imputation by Chained Equations
(mice) package [25]) were performed using R software
version 3.2.0 (2015) [26]. All other statistical analyses were
performed using SPSS version 20.0 (IBM Corporation,
New York, NY, 2013).
Deviations from the initial protocol (research proposal)
Patients were included upon physician’s clinical diagno-
sis rather than upon evaluation of whether patients met
McGeer’s surveillance criteria for pneumonia (requiring
X-ray examination) or other lower respiratory infections
[27], because we expected the additional check to dis-
courage inclusion of patients (for example, if some
symptoms were not assessed). However, 86 % of in-
cluded patients met the criteria of McGeer for other
lower respiratory infections. Further, because pre-
intervention data showed no difference in the outcomes
between patients treated with or without antibiotics,
planned analyses of the effect of treating with antibiotics
were not performed. The RDOS to assess respiratory
distress was not part of the trial protocol but was found
later and replaces the recording of a combination of
items to address respiratory difficulty. The Reaction
Level Scale was not used to assess coma, as it implies
applying pain stimuli, which is not compatible with ob-
servations by the independent observers.
Results
Pneumonia episodes and observations
Between 1 January 2012 and 1 May 2015, the attending
physicians included 464 episodes of pneumonia in the
study and reported late 131 ”missed” episodes that met
the inclusion criteria but were not reported in a timely
manner. The incidence of pneumonia was 0.085 episode
of pneumonia per resident per year. The nursing homes
that participated in the study had an average of 100 beds
(range 30–200) on one or more psychogeriatric wards.
We obtained observational data for 399 episodes in 367
residents (18 residents participated twice, 4 participatedthree times, 2 participated four times). In the remaining
65 of the 464 episodes no observations took place, mostly
due to organizational difficulties in scheduling of the ob-
servations, or because residents died soon after pneumo-
nia diagnosis. The analyzed episodes included 210
(52.6 %) in the pre-intervention phase and 189 (47.4 %) in
the intervention phase with 80 episodes in control homes
and 109 episodes in intervention homes (Fig. 2).
Characteristics of population and treatments
Overall, in 57.9 % of the episodes residents were female,
and the mean age was 84.2 (SD 7.6) (Table 2). In most
episodes (87.1 %), residents received antibiotic treat-
ment. Physicians initiated treatment to relieve symptoms
of pneumonia in 72.9 % of the episodes; antipyretics
(46.7 %), oxygen (24.9 %), and morphine (16.0 %) were
used most often. Despite cluster randomization of the
homes, we found some differences between groups and
phases (pre-intervention versus intervention) with re-
gard to resident characteristics and symptoms of pneu-
monia (Table 2 and Additional file 1: Table S1), for which
we adjusted in the analyses. Few differences were observed
in symptom-relieving treatments between control and
intervention homes and between the pre-intervention and
intervention phase (Additional file 1: Table S2); in the pre-
intervention phase, antipyretics were more common in
intervention homes (55.0 % compared to 32.7 % in control
homes), while in the intervention phase fewer residents
received oxygen in intervention homes (20.6 %) com-
pared to control homes (35.9 %).
The course of discomfort and symptoms
The highest level of discomfort (DS-DAT) was measured
on the day of diagnosis; from that point, levels declined
to reach a stable level at around day 10 (Fig. 3). Comfort
(EOLD-CAD), pain (PAINAD), and respiratory distress
(RDOS) followed a similar course (Additional file 1:
Figure S1).
Effect of the intervention on discomfort and symptoms
and secondary outcomes
Table 3 shows the effect of the intervention on the level
of discomfort and symptoms from the diagnosis until
14 days later. The intervention was not effective in redu-
cing the level of discomfort and symptoms in both un-
adjusted and adjusted models (adjusted, DS-DAT: 1.11
(95 % CI 0.93–1.31), reverse EOLD-CAD: 1.01 (95 % CI
0.98–1.05), PAINAD: 1.04 (95 % CI 0.93–1.15), RDOS:
1.11 (95 % CI 0.90–1.24)).
Discomfort and symptoms were higher for residents
who died within 20 days from the diagnosis of pneumo-
nia and lower for residents who were observed asleep. A
significant interaction between the intervention and
death within 20 days for (lack of ) comfort (EOLD-CAD)
Fig. 2 Trial profile
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(p = 0.02) indicates that the intervention was the least ef-
fective for residents who died within 20 days from the
diagnosis of pneumonia (Additional file 1: Table S3). In
unadjusted analyses, the coefficient for residents who
died within 20 days was 1.09 (>1 favors control group),
and for those who did not die it was 0.98 (<1 favors
intervention group).
The intervention effect was not different for residents
who were observed awake or asleep; adding a correction
for observed sleepiness to other adjustments did not
notably affect the magnitude or the direction of the
coefficients for the level of discomfort and symptoms
(Additional file 1: Tables S3 and S4). Coefficients were
similar with observations performed only after the first
day and when limited to the first pneumonia episode per
resident (Additional file 1: Table S5).
Change of discomfort and symptoms over the study
period
Discomfort and symptoms were significantly lower in
the intervention phase compared to the pre-intervention
phase, in both the control and the intervention homes:
adjusted, DS-DAT: 0.93 (95 % CI 0.85–1.01), EOLD-
CAD: 0.98 (95 % CI 0.97–1.00), PAINAD: 0.96 (95 % CI
0.91–1.01), RDOS: 0.92 (95 % CI 0.87–0.98) (Table 4,
Additional file 1: Table S6). Although discomfort and
symptoms decreased gradually over time, for lack ofcomfort, pain, and respiratory distress, the largest de-
crease was observed at the transition to the intervention
phase (Fig. 4, Additional file 1: Figure S2).
Discussion
We found that the physician practice guideline had no
effect on discomfort and symptoms in a cluster random-
ized trial in 32 nursing homes. However, lack of comfort
and respiratory distress gradually declined during the
3.5 years of observation in both the control and the
intervention nursing homes.
Discomfort and symptoms and effect of the intervention
Few studies have assessed discomfort in dementia resi-
dents using the DS-DAT [1, 3, 9, 28], but compared to
these earlier studies of physician observations of resi-
dents with pneumonia [2] or in the last days of life [12],
levels of discomfort in our study were particularly low.
The rate of antibiotic administration was high compared
to a previous Dutch observational study (van der Steen
et al. [1]) in which 77 % of patients with dementia and
pneumonia received antibiotic treatment compared to
87 % in our study; also, symptom-relieving treatments
including opioids were provided more often. Neverthe-
less, the decrease of discomfort and symptoms during
the study period in both control and intervention homes
shows that there was room for improvement (mean DS-
DAT score on day 3 in our 1996–1998 study: [2] 8.4;
Table 2 Resident characteristics, treatment, and mortality
Pre-intervention phase Intervention phase
Characteristics All (n = 399) Control (n = 98) Intervention (n = 112) Control (n = 80) Intervention
(n = 109)
Demographics
Female, % (n) 57.9 (231) 62.2 (61) 54.5 (61) 67.5 (54)2 50.5 (55)2
Age, mean (SD) 84.2 (7.6) 84.3 (7.3) 85.6 (6.3)1 83.7 (8.4) 83.3 (8.1)1
Length of stay, months, median (interquartile range) 18 (30) 17 (29) 23 (32) 1 22 (38) 2 12 (27) 1, 2
Dementia type, % (n)
Alzheimer’s 37.8 (151) 34.7 (34) 36.6 (41) 41.2 (33) 39.4 (43)
Vascular 21.1 (84) 21.4 (21) 21.4 (24) 21.2 (17) 20.2 (22)
Mixed 15.3 (61) 12.2 (12)2 23.2 (26)2, 1 12.5 (10) 11.9 (13)1
Other 8.3 (33) 7.1 (7) 7.1 (8) 3.8 (3)2 13.8 (15)2
Unknown 17.6 (70) 24.5 (24)2 11.6 (13)2 21.2 (17) 14.7 (16)
Dementia severity, mean BANS-S score, mean (SD) 16.1 (4.6) 15.7 (4.7) 16.6 (4.8) 15.9 (4.6) 16.0 (4.5)
Full ADL dependency, % (n) 15.1 (55) 15.1 (13) 18.0 (18)1 20.5 (16)2 8.0 (8)1, 2
Dressing 44.5 (165) 45.3 (39) 52.5 (53)1 42.9 (33) 37.0 (37)1
Walking 35.8 (129) 38.1 (32) 39.8 (39) 37.2 (29) 29.0 (29)
Eating 22 (81) 21.6 (19) 28.4 (29)1 24.4 (19) 14.0 (14)1
Hydration status,* dehydrated, % (n) 31.2 (123) 39.8 (39)1 30.6 (34) 24.4 (19)1 29.0 (31)
Clinical judgment of illness severity (range 1–9), mean (SD) 5.3 (1.5) 5.3 (1.3) 5.6 (1.5) 5.2 (1.4) 5.3 (1.6)
Prognostic score (range 0–31), mean (SD) 14.2 (5.4) 14.7 (5.6) 14.0 (5.5) 14.2 (5.9) 13.9 (5.3)
Comfort goal, % (n) 62.2 (248) 62.2 (61) 63.4 (71) 67.5 (54) 56.9 (62)
Antibiotic treatment, % (n) 87.1 (344) 89.8 (88) 88.3 (89) 82.1 (64) 86.9 (93)
Observed non-pharmacological measures** 52.9 (211) 52.0 (51) 49.1 (55) 62.5 (50) 50.5 (55)
Death within 14 days 20.2 (80) 24.7 (24) 17.1 (19) 18.8 (15) 20.2 (22)
Death within 6 months 43.6 (154) 44.6 (41) 36.9 (41) 44.9 (31) 40.6 (41)
*Hydration status as judged by the attending physician; “mildly dehydrated,” “dehydrated,” and “severely dehydrated” were combined into “dehydrated”
**Observed non-pharmacological measures during at least one observation day between day 1 and day 5 from diagnosis
1Significant difference between pre-intervention and intervention phase in control homes and intervention homes (p < 0.05)
2Significant difference between control homes and intervention homes during pre-intervention and intervention phase (p < 0.05)
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phase: 5.4).
Possible explanations for the lack of an overall inter-
vention effect may relate to the characteristics of the
practice guideline and how it was introduced to and ap-
plied by physicians. Although the practice guideline tar-
geted the attending physicians, symptom-relieving
treatments were not different in the intervention homes,
which suggests that there was no change in physicians’
prescribing behavior. Data collected in the context of a
process evaluation suggest that physicians who employed
the practice guideline did not express a pressing need to
use it because they felt that the recommendations
matched their routines already [29]. Moreover, the ob-
servational instruments for pain and respiratory distress
to monitor symptoms of pneumonia were not used regu-
larly, which may indicate suboptimal adoption. Changing
practice using interventions requires considerable effort,
and guideline adherence may have been higher if morerigorous implementation strategies had been applied
such as audit and feedback or multiple interactive
meetings.
We found that the effects of the practice guideline
were more favorable for residents who did not die within
20 days following pneumonia diagnosis. Perhaps there
was more room for improvement for these residents, as
physicians may have been less cognizant of comfort
care’s importance for residents who are not expected to
die from the pneumonia [28, 30, 31].
Decrease of discomfort and symptoms over time
Discomfort and symptoms steadily decreased throughout
3.5 years of data collection. However, the largest change oc-
curred with the transition to the intervention phase, which
may be attributable to physician’s renewed attention to
pneumonia symptoms such as pain and respiratory distress
induced by both the practice guideline’s implementation in
the intervention homes and the evaluation meeting in the
ab
Fig. 3 Mean discomfort (Discomfort Scale-Dementia of Alzheimer
Type, DS-DAT range 0–27) per observation day in control homes
(a) and intervention homes (b); pre-intervention phase compared to
intervention phase. Range among groups (pre-intervention phase,
intervention phase, intervention homes, control homes) in the number
of observations per day from pneumonia diagnosis: Day 0 (first
observation): 28–43; day 0 (second observation): 14–28; day 1 (first
observation): 54–86; day 1 (second observation): 40–66; day 2: 55–94;
day 3: 54–90; day 4: 52–79; day 5: 50–80; day 6: 50–84; day 7: 53–87;
day 8: 49–79; day 9: 53–72; day 10: 12–24; day 13: 25–56; day 14: 12–21
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better out of a sense of competition. External factors, such
as increased (media) attention for comfort and palliative
care but also focus on this topic in education and furthertraining, might account for the gradual decrease in discom-
fort and symptoms during this study. Moreover, the moni-
toring of discomfort and symptoms by external observers
may have increased awareness of nursing staff members
about the residents’ condition.
An effect of attention and increasing awareness is
called a Hawthorne effect, and it concerns participants’
awareness of being studied that may impact their behav-
ior. Studies addressing a Hawthorne effect are highly
heterogeneous [32], but they share the characteristic that
improvement of the outcome measure was due to atten-
tion or awareness and without an actual intervention, as
is the case with, e.g., hand hygiene or appropriately pre-
scribing antibiotics [33, 34]. Furthermore, participants
are observed, or alternatively feel observed, such as with
videotaping or participants being aware that their behav-
ior is monitored. Social desirability considerations may
(unconsciously or not) change behavior to be in line
with the researchers’ expectations. In our study, the
nursing staff ’s feeling of being observed perhaps led to a
greater focus on comfort or comfort measures which
may have occurred gradually over time. In this way, col-
lecting data may have been an effective intervention in
itself, and this may hold as well for other populations.
Strengths and limitations
This study is unique in the assessment of the outcomes
on a regular (almost daily) basis by observers who were
blinded to the intervention and to the residents’ treat-
ments and condition. Furthermore, we used four differ-
ent validated observational instruments to provide an
overall picture of the effects of the practice guideline on
discomfort and symptoms and its course over time.
There are some limitations that should be acknowl-
edged. First, 131 episodes fulfilled the inclusion criteria,
but the attending physicians did not include them in a
timely manner. With regard to residents’ sex, age, and
antibiotic treatment, these episodes were not different
from the episodes that were included. However, in the
65 of 464 cases that lacked observations, residents often
died soon after diagnosis. These missing data were not
at random, and the results are of course based on the
residents who survived. Second, we chose outcome mea-
sures that capture pneumonia symptoms that are the
most burdensome, but these do not necessarily cover all
symptoms of pneumonia. The symptoms observed may
have been caused by comorbid conditions or the ter-
minal phase rather than by the pneumonia, but our aim
was to assess the effect of a palliative intervention on
symptoms after developing pneumonia regardless of
causal mechanisms. Third, the proportion of residents
not treated with antibiotics was too small (12.9 %) to
perform subgroup analyses. Fourth, at times there was a
substantial time period between observations of different
Table 3 Intervention effect on levels of discomfort, (lack of) comfort, pain, and respiratory distress
Level of suffering Unadjusted analyses Adjusted analysesa
Coefficient (95 % CI) ICC Coefficient (95 % CI) ICC*
Discomfort (DS-DAT) = 1.05 (0.88–1.25) 0.12 = 1.11 (0.93–1.31) 0.13
Lack of comfort (reverse EOLD-CAD) = 1.01 (0.98–1.04) 0.10 = 1.01 (0.98–1.05) 0.14
Pain (PAINAD) = 1.01 (0.90–1.12) 0.07 = 1.04 (0.93–1.15) 0.11
Respiratory distress (RDOS) = 1.06 (0.94–1.19) 0.17 = 1.11 (0.99–1.24) 0.21
Discomfort (DS-DAT Discomfort Scale-Dementia of Alzheimer Type; range 0–27), (lack of) comfort (EOLD-CAD, End Of Life in Dementia-Comfort Assessment in
Dying; range 14–42), pain (PAINAD, Pain Assessment in Advanced Dementia; range 0–10), respiratory distress (RDOS, Respiratory Distress Observation Scale;
range 0–16)
Results from models without interaction terms of group and intervention phase with the level of observed sleepiness or death within 20 days
Analyses were performed on log-transformed data after which coefficients and confidence intervals were back-transformed. Therefore, coefficients should be interpreted
as a ratio, so that a coefficient of 1 means no difference
ICC, intracluster correlation; *ICC for adjusted analyses determined with non-imputed data for covariates
CI, confidence interval
= No significance
aAdjusted for age, sex, season, severity of dementia (BANS-S score), type of dementia (Alzheimer’s or other), death within 20 days, and baseline differences (Table
2 resident characteristics, and Additional file 1 Table S1 symptoms fo pneumonia). Adjusted analyses are performed on multiply imputed data for covariates
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observers performed the observations. However, previ-
ous work showed that repeated observations with the
DS-DAT are reliable when performed by the same obser-
ver after a number of months, and reliability is also ac-
ceptable among different observers [10]. Therefore, it is
unlikely that the way discomfort was assessed changed
substantially over time. Although it could take a while
before they assessed the next patient, in view of previous
findings, it is unlikely that the way discomfort was
assessed changed over time. Lastly, we included 16 nurs-
ing homes per group, which was — according to the
power analyses — adequate to detect relevant changes in
the main outcome (DS-DAT) and the PAINAD, but low
for the EOLD-CAD (20 per group needed). However,Table 4 Level of discomfort, (lack of) comfort, pain, and respiratory
the control homes and the intervention homes together
Level of suffering Unadjusted analyses
Coefficient (95 % CI)
Discomfort (DS-DAT) + 0.90* (0.82–0.98)
Lack of comfort (reverse EOLD-CAD) + 0.98* (0.96–0.99)
Pain (PAINAD) + 0.93* (0.88–0.99)
Respiratory distress (RDOS) + 0.91* (0.86–0.97)
Discomfort (DS-DAT Discomfort Scale-Dementia of Alzheimer Type; range 0–27), (lac
Dying; range 14–42), pain (PAINAD Pain Assessment in Advanced Dementia; range 0
range 0–16)
Results from models without interaction terms of group and intervention phase wit
Analyses were performed on log-transformed data after which coefficients and confide
as a ratio, so that a coefficient of 1 means no difference
CI confidence interval
ICC intracluster correlation; *ICC for adjusted analyses determined with non-impute
*p < 0.05
+ Significant association that is interpreted in terms of a positive attribute (favors in
respiratory distress)
= No significance
aAdjusted for age, sex, season, severity of dementia (BANS-S score), type of dement
2 resident characteristics, and Additional file 1 Table S1 symptoms fo pneumonia). Aexcept for the first two observation days, the standard
deviation in our data was lower than the standard devi-
ation we used in the power calculation. This might be
explained by higher levels and lower variability in com-
fort in residents who were not close to death, compared
to retrospective assessment after death on which we
based the power calculations (the instrument has
been used prospectively successfully in residents ex-
pected to die, and we used it prospectively for all res-
idents) [12].
Conclusions
The developed practice guideline for optimal symptom
relief had no effect on discomfort and symptoms in
nursing home residents with dementia and pneumonia.distress in intervention phase versus pre-intervention phase for
Adjusted analysesa
ICC Coefficient (95 % CI) ICC*
0.12 = 0.93 (0.85–1.01) 0.12
0.09 + 0.98* (0.97–1.00) 0.13
0.07 = 0.96 (0.91–1.01) 0.10
0.16 + 0.92* (0.87–0.98) 0.18
k of) comfort (EOLD-CAD End Of Life in Dementia-Comfort Assessment in
–10), respiratory distress (RDOS Respiratory Distress Observation Scale;
h the level of observed sleepiness or death within 20 days
nce intervals were back-transformed. Therefore, coefficients should be interpreted
d data for covariates
tervention phase: decrease in discomfort, lack of comfort, pain and
ia (Alzheimer’s or other), death within 20 days and baseline differences (Table
djusted analyses are performed on multiply imputed data for covariates
ab
Fig. 4 Mean DS-DAT score (a) and mean PAINAD score (b) (95 % confidence interval) on observation day 2 by year of data collection before and
after the start of the intervention phase in both control and intervention homes. Range of the number of observations per period: −2 years:
14–16, –1 year: 136–140, 1 year: 105–109, 2 years: 35–36. DS-DAT Discomfort Scale-Dementia of Alzheimer Type; range 0–27, PAINAD Pain
Assessment in Advanced Dementia; range 0–10
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fect may be suboptimal implementation and also the fact
that physicians often did not use the guideline because
they felt that they already worked according to its rec-
ommendations. Moreover, an intervention can be
more directive when there is a firmer scientific basis
for symptom-relieving treatment. Discomfort was particu-
larly low compared to previous research; moreover, itsteadily decreased during the study period. Possible
explanations for this favorable development are exter-
nal factors such as increased attention in media and
education or increased alertness due to the regular
observer visits. Future studies may examine if an
intervention directed at awareness of discomfort and
regular observations by the nursing staff is more ef-
fective than a physician practice guideline.
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Additional file 1: Table S1. Symptoms of pneumonia. Table S2.
Treatments. Figure S1a–f. Mean comfort (EOLD-CAD: End Of Life in
Dementia-Comfort Assessment in Dying; range 14–42) (a,b), pain (PAINAD:
Pain Assessment in Advanced Dementia; range 0–10) (c,d), and shortness of
breath (RDOS: Respiratory Distress Observation Scale; range 0–16) (e,f) per
observation day in control homes (a,c,e) and intervention homes (b,d,f);
pre-intervention phase compared to intervention phase. Figure S2. Mean
EOLD-CAD score (95 % confidence interval) (a), mean RDOS score (95 %
confidence interval) (b) on observation day 2 by year of data collection
before and after the start of the intervention phase in both control and
intervention homes. The range of the number of observations per period
varied for the different outcomes: –2 years: 14–16, –1 year: 136–140, 1 year:
105–109, 2 years: 35–36. EOLD-CAD: End Of Life in Dementia – Comfort
Assessment in Dying; (theoretical) range 14–42, RDOS: Respiratory Distress
Observation Scale; range 0–16. Table S3. Secondary outcomes: testing of
possible differential intervention effects by observed sleepiness and death
within 20 days. Table S4. Exploratory analyses: intervention effect on levels
of discomfort, (lack of) comfort, pain, and shortness of breath, and on
change of the outcomes over time adjusted for the level of observed
sleepiness. Table S5. Sensitivity analysis: intervention effect on levels of
discomfort, (lack of) comfort, pain, and shortness of breath, and on change of
the outcomes over time, without day 0. Table S6. Level of discomfort,
(lack of) comfort, pain, and shortness of breath in intervention phase versus
pre-intervention phase in control homes and intervention homes. (DOC 402 kb)
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